source
- Moderna raises $2 billion after Phase 3 success of its algorithm-driven personalized cancer vaccine with MerckModerna announced a $2 billion convertible debt financing, a move that follows the Phase 3 success of its personalized cancer vaccine developed with Merck. The vaccine relies on software that scan…
- FDA approves Revolution Medicines' first genetic-targeted therapy for advanced pancreatic cancerThe U.S. Food and Drug Administration has granted approval for a new treatment developed by Revolution Medicines aimed at patients with advanced pancreatic cancer. The therapy is designed to extend…